KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Work In Process (2016 - 2026)

Edwards Lifesciences has reported Work In Process over the past 12 years, most recently at $252.9 million for Q4 2025.

  • For Q4 2025, Work In Process rose 7.07% year-over-year to $252.9 million; the TTM value through Dec 2025 reached $252.9 million, up 7.07%, while the annual FY2025 figure was $252.9 million, 7.07% up from the prior year.
  • Work In Process for Q4 2025 was $252.9 million at Edwards Lifesciences, down from $275.9 million in the prior quarter.
  • Over five years, Work In Process peaked at $275.9 million in Q3 2025 and troughed at $195.8 million in Q4 2023.
  • A 3-year average of $247.0 million and a median of $252.9 million in 2025 define the central range for Work In Process.
  • Biggest five-year swings in Work In Process: grew 20.63% in 2024 and later increased 0.62% in 2025.
  • Year by year, Work In Process stood at $195.8 million in 2023, then grew by 20.63% to $236.2 million in 2024, then grew by 7.07% to $252.9 million in 2025.
  • Business Quant data shows Work In Process for EW at $252.9 million in Q4 2025, $275.9 million in Q3 2025, and $261.4 million in Q2 2025.